Who are High Dose Enoxaparin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Usual dose adjustment of enoxaparin, Tinzaparin continuous infusion, dalteparin injection, Low dose nadroparin, Intermediate dose dalteparin, normal injection of Enoxaparine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/high-dose-enoxaparin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

High Dose Enoxaparin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High Dose Enoxaparin (High Dose Enoxaparin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Low-molecular-weight heparin (LMWH). Area: Cardiovascular.

marketed Low-molecular-weight heparin (LMWH) Coagulation factors Xa and IIa (via antithrombin III) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

High Dose Enoxaparin (High Dose Enoxaparin) — Oregon Health and Science University. High-dose enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
High Dose Enoxaparin TARGET	High Dose Enoxaparin	Oregon Health and Science University	marketed	Low-molecular-weight heparin (LMWH)	Coagulation factors Xa and IIa (via antithrombin III)
Usual dose adjustment of enoxaparin	Usual dose adjustment of enoxaparin	Assistance Publique - Hôpitaux de Paris	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa and Factor IIa (via antithrombin III)
Tinzaparin continuous infusion	Tinzaparin continuous infusion	Tampere University Hospital	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (enhancer); Factor Xa and Factor IIa (indirect targets)
dalteparin injection	dalteparin injection	University of Rochester	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (Factor Xa and Factor IIa)
Low dose nadroparin	Low dose nadroparin	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa, Thrombin (Factor IIa)
Intermediate dose dalteparin	Intermediate dose dalteparin	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (indirect); Factor Xa and Thrombin (downstream targets)
normal injection of Enoxaparine	normal injection of Enoxaparine	French Cardiology Society	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa and Factor IIa (via antithrombin III enhancement)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Low-molecular-weight heparin (LMWH) class)

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 7 drugs in this class
University of Melbourne · 3 drugs in this class
French Cardiology Society · 2 drugs in this class
Ottawa Hospital Research Institute · 2 drugs in this class
McMaster University · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
GlaxoSmithKline · 1 drug in this class
IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
Cristália Produtos Químicos Farmacêuticos Ltda. · 1 drug in this class
Helsinki University Central Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). High Dose Enoxaparin — Competitive Intelligence Brief. https://druglandscape.com/ci/high-dose-enoxaparin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing